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it is important to explore the behavior change techniques (BCTs) employed and 
their contribution to pooled effectiveness. This paper aimed to estimate the pooled 
effectiveness of OAD adherence-enhancing interventions and identify BCTs applied 
that had a modifying effect on the pooled estimate of effectiveness. Methods: We 
performed a systematic review and meta-analysis of RCTs conducted to evaluate 
the effectiveness of adherence-enhancing interventions targeting adults receiv-
ing OADs. Articles were searched using PubMed, Embase, Psych-Info, the Cochrane 
Library, CINAHL PLUS, Current Contents Connect and Web of science, and included 
articles references and relevant review articles. Two authors independently selected 
eligible articles and coded study details including BCTs applied in intervention 
and control groups. Each intervention’s effectiveness (effect size) was estimated 
using Hedges’s g. Pooled effectiveness and its heterogeneity (Higgins I2) were esti-
mated using a random effect model. For BCTs applied in intervention but not in 
control groups, we assessed their modifying effect on the pooled effectiveness by 
comparing interventions in which a specific BCT was applied with those in which 
it was not. Results: A total of 10 studies were included. Globally, the pooled effec-
tiveness (g) was 0.21 (95%CI= -0.05–0.47; I2= 82%). Out of eight BCTs analysed, cope 
with side-effects (P= 0.003) and general intention formation (P= 0.006) had a modifying 
effect on the pooled effectiveness. The pooled effectiveness of interventions, in 
which cope with side-effects was applied, was moderate (g= 0.64; 95%CI= 0.31–0.96; 
I2= 56%). ConClusions: Globally, effectiveness of interventions offered in inter-
vention groups was almost equivalent to that of those offered in control groups. 
However, interventions that include helping people to cope with side-effects, when 
this was not done for control patients, are particularly effective in improving adher-
ence to OAD.
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objeCtives: Pharmaceutical expenditure is determined by both price and volume. 
Volume control is important despite that public policies to control drug expenditure 
in Korea have focused on price control. In this study, we decomposed growth of 
diabetes drug expenditure in Korea. Methods: The study used National Health 
Insurance Service (NHIS) claims data on diabetes drugs for 10 years between January 
1, 2003 and December 31, 2012. We included new or incrementally modified diabetes 
drugs for which listing prices were negotiated between firms and NHIS and their 
generic counterparts. Drug expenditure was decomposed into price and volume. 
Volume is further decomposed into the proportion of monthly volume for each drug 
in its therapeutic class (composition mix), the proportion of sum of quantity used 
in new and existing drugs (therapeutic mix) for a given therapeutic group, and the 
total volume used for new and existing drugs (total volume). We generated Fisher’s 
Ideal Index to calculate contribution of each component of total drug expenditure 
to its growth. Results: The price of diabetes drugs as a whole decreased total drug 
expenditure since 2006, whereas growth of volume explained most of the growth 
of total pharmaceutical expenditure during 2006 and 2010. Particularly between 
2011 and 2012 when price decreased 12% due to nationally implemented price 
cut for almost all listed drugs, the volume still increased 5%. Further decomposi-
tion of volume showed that the change in the proportion of volume of new diabe-
tes drugs in total volume minimally contributed to growth in total diabetes drug 
expenditure. ConClusions: Our results showed that growth in quantity (volume) 
index explained most of the growth in total pharmaceutical expenditure for diabe-
tes drugs, whereas price index overall decreased for the same time period. These 
results imply that volume control is more critical for policy measured related to 
drug expenditure control.
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objeCtives: Lipohypertrophy (LH) is a relatively common complication of injecting 
insulin. It is reported to impair insulin absorption, and may increase total daily dose 
(TDD) of insulin and associated costs. The economic burden of LH is unknown in 
China. This study aims to evaluate the effects of LH on TDD of insulin and explore 
potential health economic implications for China. Methods: The following data 
were extracted from literature review and the IMS Health Report (Diabetes China 
2013): (i) insulin-injecting diabetes population in China1, (ii) prevalence of LH among 
insulin-injecting Chinese patients2, (iii) TDD of insulin among patients with LH 
(estimated from a recent Spanish study3), (iv) average unit cost of insulin in China1. 
Cost of excess insulin use was calculated per annum. All monetary values were 
converted to 2013 RMB, with a RMB-USD exchange rate of 6.14:1. Results: There 
are approximately 8.4 million insulin injectors in China, mostly type 2 diabetes 
(T2D)1. The prevalence of LH in China was previously reported to be 31%2. In the 
Spanish study, patients with T2D and LH used 21 IU/day more insulin3; we estimated 
15 IU/day excess usage vs non-LH injectors in China. The average insulin price in 
China is 0.215 RMB per IU1. The estimated cost of excess insulin use due to LH is 
approximately 3,065,233,500 RMB ($498,991,500 USD) per year. ConClusions: LH 
may represent a significant, addressable, economic burden in China due to excess 
insulin consumption. Taking steps to reduce LH may reduce health care costs in 
China. Additional studies should be conducted on LH prevalence, glycemic control 
(HbA1c, hyper- and hypoglycemia) and health resource utilization patterns spe-
cifically among the Chinese insulin-injecting population to validate and extend 
these findings.
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factors driving to increases in diabetes medication costs from 2000 to 2010. Changes 
in diabetes drug spending are decomposed to eight components: (1) the growth of 
user population; (2) the growth of number of prescription per user; (3) the growth 
of number of drug item of per prescription of established drugs; (4) the growth of 
number of drug item of per prescription of new entrant drugs; (5) the growth of 
Defined Daily Dose (DDD) of established drugs of average drug item per prescrip-
tion; (6) the growth of DDD of new entrant drugs of average drug item per prescrip-
tion; (7) change of average price of established drugs per prescription ; (8) change 
of average price of new entrant drugs per prescription; (9) change in therapeutic 
and strength mix. Results: Changes in user population, number of drug item of 
per prescription, and therapeutic and strength mix caused diabetes spending to 
increase. The drug price and DDD caused diabetes spending to decrease. Over half 
of drug spending growth was accounted for user population. The rest of spending 
growth was from the change in drug treatment intensity. The results also reveal 
the care pattern change to more drug item with low-dose therapy. ConClusions: 
The results suggest that use drug pricing policy to lower drug spending is limited. 
The policy makers should consider put more effort to manage treatment intensity 
in diabetes medication.
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objeCtives: Physicians’ generic pharmaceutical adoption are responsible for 
patients, insurance payers, and their own interests. This study examines this dou-
ble agency problem for physicians by using Taiwanese data, because physicians 
can both prescribe and dispense drugs in Taiwan. The universal health care system 
in Taiwan also causes the problem to be a public concern. Methods: This study 
begins with a theoretical model of physicians’ prescription behavior that includes 
both the patients’ and physicians’ utilities, and government’s share of patients’ 
medical expenditure. To empirically estimate this model by using the Taiwanese 
data, a panel framework is structured by adopting visit-physician-drug as a unit 
of observation. Empirical results were obtained after controlling the physicians’, 
patients’, and hospitals’ characteristics; and time-, location-, and drug-fixed effects. 
The physicians’ unobserved, time-invariant heterogeneity was also controlled by 
applying Chamberlain’s correlated random effects probit model. Results: The 
empirical results show that a larger price difference between brand-name and 
generic drugs increases physicians’ likelihood for prescribing generic prescriptions. 
However, for physicians in hospitals, this effect decreases as the payer’s cost share 
percentage increases. These results indicate that physicians’ prescriptions decision 
internalize patients’ utility but not the payer’s cost. This study also demonstrates 
that physicians who are more responsive to profits prescribed more generic drugs, 
including owners of hospitals and clinics, and physicians in clinics and private 
institutions. However, this effect decreases as the number of competitors in the drug 
market increases. ConClusions: The reported findings suggest that physicians’ 
double agent role in a universal health care system is responsible for part of the 
pharmaceutical expenditure in Taiwan, where brand-name drugs were probably 
prescribed more than necessary. Taiwanese government is advised to encourage 
generic prescriptions by providing incentives for physicians, increasing the patients’ 
share of their medication cost, and increasing patients’ and physicians’ access to 
the information on generic drugs.
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objeCtives: Among individuals newly treated with oral antidiabetes drugs (AD), 
to assess the effect of pharmacy loyalty on compliance with AD and on the use of 
guidelines-recommended medications: 1) ACE inhibitor (ACEi) or angiotensin recep-
tor blocker (ARB); 2) lipid-lowering drug. Methods: Using Quebec administrative 
databases we carried out a cohort study of individuals aged ≥ 18 years who had 
started an OAD between 2000 and 2006 and for whom we had at least 3 years of 
follow-up after OAD initiation. Individuals who had filled all their prescriptions in 
the same pharmacy during the 2nd year after OAD initiation were considered loyal. 
Compliance with OAD (Medication Possession Ratio ≥ 80%) and use of an ACEi/ARB 
and of a lipid-lowering drug were measured in the 3rd year. Outcomes were assessed 
using multivariate logistic regressions. Results: Among 97,927 eligible individuals, 
64% were loyal to their pharmacy, 64% were compliant with their AD, 64% used an 
ACEI/ARB and 60% used a lipid-lowering drug. Loyal individuals were more likely to 
be compliant with their AD (Odds ratio: 1.26; 95% CI: 1.22-1.30), to use an ACEI/ARB 
(1.17; 1.14-1.21) and to use a lipid-lowering drug (1.15; 1.12-1.18). ConClusions: 
Pharmacy loyalty is associated with a better quality of AD use. It is likely due to 
the fact that pharmacists can better play their role in optimizing their clients’ drug 
use for patients loyal to their pharmacy as they can then rely on recorded drug use 
information that is comprehensive.
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objeCtives: OAD adherence interventions are available but their pooled effective-
ness has not yet been estimated. Also, in order to develop effective interventions, 
